Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Canada Postdoctoral Research Award (CPRA) program

Direct Payment

$140,000.00

Identification of novel therapeutic strategies for glioblastoma by targeting the influence of microglia-macrophages on tumor cells

FY 2025-26

Summary
Glioblastoma is the most common and aggressive brain cancer in adults. Despite surgery, radiation, and chemotherapy, survival is only 15 months after diagnosis. A key reason for this poor outcome is that glioblastoma is highly resistant to treatment and almost always comes back after therapy. This resistance is partly driven by how the tumor interacts with immune cells normally found in the brain. Among these immune cells are microglia and macrophages, which can be "reprogrammed" by the tumor to support its growth and help it hide from the immune system. These supportive immune cells are called tumor-associated microglia/macrophages (TAMs), and can make up a third of the tumor. Research from the Kristensen lab has shown that one particular type of TAMs (CD204+) is linked to worse patient outcomes, but we still don't fully understand what they do or how to stop them. This project aims to identify exactly how CD204-positive TAMs help the tumor grow and resist therapy. We will use a special mouse model that allows us to remove these immune cells and study how tumors behave when they're gone. We'll use advanced technologies to track changes in tumor behavior and gene activity. Based on this, we'll identify potential targets (genes or proteins) that might be blocked to stop tumor growth. Next, we will examine how these targets behave in actual human tumor samples. We will prioritize targets that are already linked to approved drugs, allowing for quicker clinical testing. Finally, we will test the most promising targets in patient-derived tumor organoids (3D mini-tumors) and in preclinical mouse models, to see if they improve sensitivity to chemotherapy. This research will provide new insight into how immune cells influence glioblastoma and could lead to faster development of new treatment strategies, including repurposing of existing drugs. If successful, this work could improve outcomes for patients and accelerate the development of personalized therapies.
Program
Canada Postdoctoral Research Award (CPRA) program
Location
Denmark
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
537868
Name
McDermott Alec
Country
Denmark
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Identification of novel therapeutic strategies for glioblastoma by targeting the influence of microglia-macrophages on tumor cells
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Glioblastoma; Patient-Derived Organoids; Spatial Transcriptomics; Therapy Resistance; Tumor Microenvironment; Tumor-Associated Macrophages And Microglia; Xenograft Models
Abstract
Glioblastoma is the most common and aggressive brain cancer in adults. Despite surgery, radiation, and chemotherapy, survival is only 15 months after diagnosis. A key reason for this poor outcome is that glioblastoma is highly resistant to treatment and almost always comes back after therapy. This resistance is partly driven by how the tumor interacts with immune cells normally found in the brain. Among these immune cells are microglia and macrophages, which can be "reprogrammed" by the tumor to support its growth and help it hide from the immune system. These supportive immune cells are called tumor-associated microglia/macrophages (TAMs), and can make up a third of the tumor. Research from the Kristensen lab has shown that one particular type of TAMs (CD204+) is linked to worse patient outcomes, but we still don't fully understand what they do or how to stop them. This project aims to identify exactly how CD204-positive TAMs help the tumor grow and resist therapy. We will use a special mouse model that allows us to remove these immune cells and study how tumors behave when they're gone. We'll use advanced technologies to track changes in tumor behavior and gene activity. Based on this, we'll identify potential targets (genes or proteins) that might be blocked to stop tumor growth. Next, we will examine how these targets behave in actual human tumor samples. We will prioritize targets that are already linked to approved drugs, allowing for quicker clinical testing. Finally, we will test the most promising targets in patient-derived tumor organoids (3D mini-tumors) and in preclinical mouse models, to see if they improve sensitivity to chemotherapy. This research will provide new insight into how immune cells influence glioblastoma and could lead to faster development of new treatment strategies, including repurposing of existing drugs. If successful, this work could improve outcomes for patients and accelerate the development of personalized therapies.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
McDermott, Alec
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~